Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (EOC)

Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved PD-L1 IHC ...
Pharmabiz

US FDA approves Agilent’s PD-L1 IHC 22C3 pharmDx, a companion diagnostic indicated to identify patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma

US FDA approves Agilent’s PD-L1 IHC 22C3 pharmDx, a companion diagnostic indicated to identify patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma Santa Clara, California ...
pharmaphorum

MSD claims two national priority vouchers; report

The next two discretionary priority vouchers to be awarded by the FDA are reported to be heading for two MSD candidates with blockbuster potential. According to Reuters, MSD – known as Merck & Co in ...
pharmaphorum

MSD, Moderna start phase 3 adjuvant lung cancer trial

MSD and Moderna have kicked off another phase 3 trial of their personalised cancer vaccine V940 used alongside MSD's PD-1 inhibitor Keytruda, this time focusing on patients with earlier-stage ...
News Medical

7820A GC System from Agilent Technologies

The 7820A Gas Chromatography system is an affordable, high-quality GC instrument for small to medium-sized labs concerned with routine analyses. This system provides modern capabilities for a wide ...
News Medical

Cary 620 FTIR Microscopes from Agilent Technologies

The Agilent Cary 610 and Cary 620 FTIR Microscopes and Chemical Imaging systems represent the latest in cutting-edge performance. Leveraging off the latest in technological developments, the systems ...